Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Thyroxine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB known ✓ | P10828 | 11/20 | 0.97 |
| ▸ | THRA known ✓ | P10827 | 7/20 | 0.97 |
| ▸ | MEN1 | O00255 | 7/20 | 0.97 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.97 |
| ▸ | LMNA | P02545 | 5/20 | 0.97 |
| ▸ | PPARG | P37231 | 5/20 | 0.97 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.97 |
| ▸ | USP2 | O75604 | 3/20 | 0.97 |
| ▸ | TTR | P02766 | 2/20 | 0.97 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.97 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.97 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.97 |
| ▸ | RXRA | P19793 | 2/20 | 0.97 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.97 |
| ▸ | MAPT | P10636 | 2/20 | 0.97 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.97 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.97 |
| ▸ | HTR1A | P08908 | 1/20 | 0.97 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.97 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.97 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Thyroxine SCHEMBL2014581 | 1.00 | THRB (0.97) | THRBMEN1KMT2ATHRALMNA | |
| Dextrothyroxine SCHEMBL1477972 | 1.00 | THRB (0.97) | THRBMEN1KMT2ATHRALMNA | |
| Levothyroxine SCHEMBL1997042 | 1.00 | THRB (0.97) | THRBMEN1KMT2ATHRALMNA | |
| Levothyroxine SCHEMBL1995241 | 1.00 | THRB (0.97) | THRBMEN1KMT2ATHRALMNA | |
| Levothyroxine SCHEMBL3421376 | 0.99 | THRB (0.95) | THRBMEN1KMT2ATHRALMNA | |
| Levothyroxine SCHEMBL23098 | 0.99 | THRB (1.00) | THRBMEN1KMT2ATHRALMNA | |
| Levothyroxine SCHEMBL4997979 | 0.99 | THRB (1.00) | THRBMEN1KMT2ATHRALMNA | |
| Thyroxine SCHEMBL4575383 | 0.99 | THRB (1.00) | THRBMEN1KMT2ATHRALMNA | |
| Thyroxine SCHEMBL11131863 | 0.99 | THRB (1.00) | THRBMEN1KMT2ATHRALMNA | |
| Dextrothyroxine SCHEMBL30885760 | 0.99 | THRB (1.00) | THRBMEN1KMT2ATHRALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 219 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119185221-A | Orally disintegrating microplatelet of levothyroxine sodium and preparation method thereof | 石河子大学 | 2024-12-27 | — | — | CN | claimed |
| CN-114694836-B | Assessment system based on thyroid cancer lymph node metastasis prediction model | 上海交通大学医学院附属瑞金医院 | 2024-06-04 | — | — | CN | claimed |
| CN-117919171-B | Preparation method of levothyroxine sodium oral liquid | 泊诺(天津)创新医药研究有限公司 | 2024-05-31 | — | — | CN | claimed |
| CN-117919171-A | Preparation method of levothyroxine sodium oral liquid | 泊诺(天津)创新医药研究有限公司 | 2024-04-26 | — | — | CN | claimed |
| CN-114097710-B | Construction method and application of animal model with myocardial hypertrophy and osteoporosis | 成都合拓创展生物科技有限公司 | 2023-03-31 | — | — | CN | claimed |
| CN-216879247-U | Levothyroxine sodium production is with quantitative conveying equipment | 天津九海医药科技有限公司 | 2022-07-05 | — | — | CN | claimed |
| CN-216834548-U | Filling equipment is used in levothyroxine sodium production | 天津九海医药科技有限公司 | 2022-06-28 | — | — | CN | claimed |
| CN-114097710-A | Construction method and application of animal model with myocardial hypertrophy and osteoporosis | 成都合拓创展生物科技有限公司 | 2022-03-01 | — | — | CN | claimed |
| US-20180030408-A1 | Culture Medium for In-Vitro Cultivation of Mycobacterium Leprae (M. Leprae) | PAL DEBAPRASAD (IN) | 2018-02-01 | — | — | US | claimed |
| US-9498539-B2 | Affinity-based controlled release system | SHOICHET MOLLY SANDRA (US) | 2016-11-22 | — | — | US | claimed |
| CN-102458543-A | Dry powder inhalers | 3M INNOVATIVE PROPERTIES CO | 2012-05-16 | — | — | CN | claimed |
| WO-2011072399-A1 | INJECTABLE POLYMER COMPOSITION FOR USE AS A CELL DELIVERY VEHICLE | THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) | 2011-06-23 | — | — | WO | claimed |
| US-20100285113-A1 | ENHANCED STABILITY OF INVERSE THERMAL GELLING COMPOSITE HYDROGELS | THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) | 2010-11-11 | — | — | US | claimed |
| US-7767656-B2 | Blends of temperature sensitive and anionic polymers for drug delivery | SHOICHET MOLLY S | 2010-08-03 | — | — | US | claimed |
| CN-101453993-A | Controlled release delivery device containing organosol coating | ISA ODIDI (CA) | 2009-06-10 | — | — | CN | claimed |
| US-20060280797-A1 | Blends of temperature sensitive and anionic polymers for drug delivery | SHOICHET MOLLY S | 2006-12-14 | — | — | US | claimed |
| EP-1599190-A2 | CONTROLLED RELEASE MODIFYING COMPLEX AND PHARMACEUTICAL COMPOSITIONS THEREOF | Glenmark Pharmaceuticals Limited (IN) | 2005-11-30 | — | — | EP | claimed |
| US-20040185097-A1 | Controlled release modifying complex and pharmaceutical compositions thereof | GLENMARK PHARMACEUTICALS LTD. | 2004-09-23 | — | — | US | claimed |
| WO-2004066910-A2 | CONTROLLED RELEASE MODIFYING COMPLEX AND PHARMACEUTICAL COMPOSITIONS THEREOF | GLENMARK PHARMACEUTICALS LTD. (US) | 2004-08-12 | — | — | WO | claimed |
| US-5917087-A | IODINATION OF TYROSINE, FOLLOWED BY REMOVAL OF EXCESS OF IODINE, ACETYLATION OF INTERMEDIATE WITH ACETIC ANHYDRIDE AND A BASE, ESTERIFICATION OF THE FORMED PRODUCT, OXIDATITIVE COUPLING IN AIR WITH MANGANESE SALT, BORIC ACID AND AMINE | KNOLL AKTIENGESELLSCHAFT (DE) | 1999-06-29 | — | — | US | claimed |